Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY20 Earnings Guidance
Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus estimate of $2.47. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $17.14 billion.Teva Pharmaceutical Industries also updated its FY 2020
Pre-Market guidance to 2.30-2.55 EPS.
Shares of TEVA stock traded down $0.35 during mid-day trading on Friday, hitting $12.22. The company’s stock had a trading volume of 32,751,698 shares, compared to its average volume of 20,229,316. The company’s fifty day simple moving average is $10.37 and its 200-day simple moving average is $8.73. Teva Pharmaceutical Industries has a 52 week low of $6.07 and a 52 week high of $18.08. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.56 and a current ratio of 0.89. The company has a market cap of $13.49 billion, a PE ratio of -3.16, a P/E/G ratio of 1.24 and a beta of 1.84.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. The firm had revenue of $4.47 billion during the quarter, compared to analyst estimates of $4.35 billion. During the same period last year, the company posted $0.53 EPS. The business’s quarterly revenue was up 1.1% on a year-over-year basis. On average, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.27 earnings per share for the current year.
In other news, VP David Matthew Stark sold 12,538 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $12.24, for a total value of $153,465.12. Following the completion of the sale, the vice president now directly owns 15,512 shares in the company, valued at approximately $189,866.88. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Hafrun Fridriksdottir sold 4,310 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.49, for a total value of $45,211.90. Following the transaction, the vice president now owns 24,883 shares of the company’s stock, valued at approximately $261,022.67. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,647 shares of company stock valued at $257,561. 0.49% of the stock is currently owned by company insiders.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: What is a stock portfolio tracker?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.